Cannabis Science Inc (OTCMKTS:CBIS) is a penny play that’s clearly begun to spur some interest among players in the marketplace as shares bounce up off recent lows. The big catalyst last week was the company’s announcement that its expansions plans are well underway as it negotiates to purchase two medical marijuana dispensaries in the Los Angeles area.
According to the release, both dispensaries will be branded Cannabis Science and showcase company products as well as other selected brands. The Company is excited to improve patient access to new drug development initiatives, and allow the Company to work much closer with its self-medicating patient base. The Company is expecting to announce the signing of the closing documents and introduce the locations shortly.
Cannabis Science Inc (OTCMKTS:CBIS) has been down an interesting road over recent months. We see the company as actively striving for, and achieving a bump in legitimacy through some of its newly established relationships.
The company defines itself according to the narrative of a leading-edge researcher and designer of cannabinoid solutions to health problems.
CBIS is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.
Cannabis Science Inc also has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug.
In addition, CBIS offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.
Find out when $CBIS stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
This stock has recently snapped back after a serious technical breach of support. Now, the question stands as to whether or not we will an erosion back down to eat the tail of the support spike, or if that support was built of buyers who will continue to aggressively accumulate on the bid.
This recent move to a more branded physical customer interface is an interesting dimension. The company plans at this point to continue in that direction. According to the release, “Cannabis Science has been working diligently toward launching this very important phase of growth. The Company is looking to open 15 -20 locations throughout California in phase one through the acquisition or partnering with existing compliant dispensary locations, as well as the complete buildout of brand new locations. This is one of many planned vertical integration strategies well underway at CBIS.”
The release also contained another key message: “Moving forward, the Company is seeking new opportunities in the way of both dispensaries and cannabis grow land acquisitions across the country. This will give the Company access to a much larger patient base, a more efficient supply chain process, and ultimately higher sales and profit margins on top of the branding benefits from having an expanded footprint from coast to coast”
We would once again remind the reader that this is all coming from a company that has created billions of shares over many years without really ever making any money. That doesn’t necessarily mean they will continue to fail to execute in operations. But it should provide one with an important dose of perspective.
Traders will note 3% tacked on to share pricing for the company in the past week. This is emblematic of the stock. CBIS has evidenced sudden upward volatility on many prior occasions. Furthermore, the company has seen interest climb, with an increase in recent trading volume of 13% beyond what we have been seeing over the larger time frame.
At this time, carrying a capital value in the market of $202.8M, CBIS has virtually no reported cash on the books, which must be weighed relative to about $2.1M in total current liabilities. One should also note that debt has been growing over recent quarters. You can bet we will update this one again as new information comes into view. For continuing coverage on shares of $CBIS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!